Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium

British Journal of Ophthalmology

Volumn 84, Issue 2, 2000, Pages 212-216

  Tan, Donald T H ^a   Tang, Wen Ying ^b   Liu, Yan Ping ^a   Goh, Hak Su ^b   Smith, Duncan R ^b  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CLINICAL ARTICLE; CONJUNCTIVA; CONTROLLED STUDY; DISEASE COURSE; EPITHELIUM; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NICK END LABELING; PATHOGENESIS; PRIORITY JOURNAL; PTERYGIUM; TROPICAL DISEASE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CONJUNCTIVA; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PTERYGIUM; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034101531     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.84.2.212     Document Type: Article

References (29)

1. Spraul CW, Grossniklaus HE. Tumors of the cornea and conjunctiva. Curr Opin Ophthalmol 1996;7:28-34.
2. Hill JC, Maske R. Pathogenesis of pterygium. Eye 1989;3:218-26.
3. Clear AS, Chirambo MC, Hutt MS. Solar keratosis, pterygium, and squamous cell carcinoma of the conjunctiva in Malawi. Br J Ophthalmol 1979;63:102-9.
4. Tan DT, Lim AS, Goh HS, et al. Abnormal expression of the p53 tumour suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol 1997;123:404-5.
5. Dushku N, Reid TW. P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res 1997;16:1179-92.
6. Tan DT, Chee SP, Dear KB, et al. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol 1997;115:1235-40.
7. Jap A, Chan C, L Li, et al. Conjunctival rotation autograft for pterygium. Ophthalmology 1999;106:67-71.
8. Karukonda SR, Thompson HW, Beuerman RW, et al. Cell cycle kinetics in pterygium at three latitudes. Br J Ophthalmol 1995;79:313-7.
9. Mackenzie FD, Hirst LW, Battistutta D, et al. Risk analysis in the development of pterygia. Ophthalmology 1992; 99:1056-61.
10. Moran DJ, Hollows FC. Pterygium and ultraviolet radiation: a positive correlation. Br J Ophthalmol 1984;68 343-6.
11. Taylor HR. Ultraviolet radiation and the eye: an epidemiologic study. Trans Am Ophthalmol Soc 1989;87:802-53.
12. Spandidos DA, Sourvinos G, Kiaris H, et al. Microsatellite instability and loss of heterozygosity in human pterygia. Br J Ophthalmol 1997;81:493-6.
13. Detorakis ET, Sourvinos G, Tsamparlakis J, et al. Evaluation of loss of heterozygosity and microsatellite instability in human pterygium: clinical correlations. Br J Ophthalmol 1998;82:1324-8.
14. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 1992;119:490-501.
15. Hsu S-M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981;29:577-80.
16. DeLong MJ. Apoptosis: a modulator of cellular homeostasis and disease states. Ann NY Acad Sci 1998; 842:82-90.
17. Eastman A. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Sem Cancer Biol 1995;6:45-52.
18. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
19. Savitz SI, Rosenbaum DM. Apoptosis in neurological disease. Neurosurgery 1998;42:555-72.
20. Oltvai ZN, Milliman CL, Korsmayer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-19.
21. Yang E, Zha J, Jockel J, et al. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
22. Miyashita T, Harigai M, Hanada M, et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
23. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 8:293-9.
24. Rodrigues NR, Rowan A, Smith ME, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555-9.
25. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
26. Selkirk JK, He C, Patterson RM, et al. Tumor suppressor p53 gene forms multiple isoforms: evidence for single locus origin and cytoplasmic complex formation with heat shock proteins. Electrophoresis 1996;17:1764-71.
27. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991;65:765-74.
28. Onur C, Orhan D, Orhan M, et al. Expression of p53 protein in pterygium. Eur J Ophthalmol 1998;8:157-61.
29. Gannon JV, Greaves R, Iggo R, et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.